All In Biotech

Drug Trial Radar · NCT06097728

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 863 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

863

Actual

Start

Nov 9, 2023

Primary completion

Nov 16, 2028

Study completion Nov 16, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Conditions

  • Unresectable Pleural Mesothelioma

Interventions

  • VolrustomigDrug

    MEDI5752: Administered as IV infusion

  • PemetrexedDrug

    Alimta: Administered as IV infusion

  • CarboplatinDrug

    Paraplatin: Administered as IV infusion

  • CisplatinDrug

    Platinol: Administered as IV infusion

  • NivolumabDrug

    Opdivo: Administered as IV infusion

  • IpilimumabDrug

    Yervoy: Administered as IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in experimental arm relative to comparator armTime frame: up to approximately 61 months

Locations

151 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Site

    Santa Rosa, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Jacksonville, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Commack, New York

  • Research Site

    Columbus, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Houston, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Chermside, Australia

  • Research Site

    Clayton, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    Westmead, Australia

  • Research Site

    Anderlecht, Belgium

  • Research Site

    Antwerp, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Hasselt, Belgium

  • Research Site

    Sint-Niklaas, Belgium

  • Research Site

    Barretos, Brazil

  • Research Site

    Fortaleza, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Guangzhou, China

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.